Recruiting at 2 sites Phase 1, Phase 2 Sickle Cell Disease

Sickle Cell Disease study: Arginine

Official title Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease

ClinicalTrials.gov ID: NCT02447874

What this study is testing

What is Arginine?

Arginine is an investigational medicine, given as an IV infusion (through a vein), being studied as a potential treatment for sickle cell disease.

Also referred to as Arginine Hydrochloride Injection, R-Gene® 10.

Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.

What it's testing
This study wants to find out if giving extra arginine lowers pain levels, reduces the need for pain medicine, or shortens hospital stays during painful episodes.
Who it's for
Children with sickle cell disease who are seeking treatment for painful episodes.
What's involved
Participants will receive extra arginine and have their pain levels, medication use, and visit duration tracked.
Time commitment
The duration and specific visit schedule are not listed in the provided text.
  • Phase 2: a mid-size study of how well it works

A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.

Who can take part

Ages 7 to 21

You may be able to join if

  • Established diagnosis of sickle cell disease--Hemoglobin SS (Hb-SS) or Sβᴼ-thalassemia
  • 7-21 years of age
  • Weight \>= 25kg (55lbs)
  • Pain requiring medical care in an acute care setting (emergency department (ED), hospital ward, day hospital, clinic) requiring parenteral opioids...

You likely can't join if

  • Decision to discharge home from acute care setting.
  • Diagnosis of sickle cell disease with any of the following types: hemoglobin SC disease (HbSC), hemoglobin beta thalassemia (Hb-Beta Thal)...
  • Hemoglobin less than 5 gm/dL
  • Immediate Red cell transfusion anticipated
  • Renal dysfunction: Creatinine \>1.0 or 2 x baseline
  • Mental status or neurological changes
See the full eligibility criteria
Who can join
  • Established diagnosis of sickle cell disease--Hemoglobin SS (Hb-SS) or Sβᴼ-thalassemia
  • 7-21 years of age
  • Weight \>= 25kg (55lbs)
  • Pain requiring medical care in an acute care setting (emergency department (ED), hospital ward, day hospital, clinic) requiring parenteral opioids, not attributable to non-sickle cell causes.
What rules you out
  • Decision to discharge home from acute care setting.
  • Diagnosis of sickle cell disease with any of the following types: hemoglobin SC disease (HbSC), hemoglobin beta thalassemia (Hb-Beta Thal), hemoglobin SD disease (HbSD), hemoglobin SE disease (HbSE), hemoglobin SO...
  • Hemoglobin less than 5 gm/dL
  • Immediate Red cell transfusion anticipated
  • Renal dysfunction: Creatinine \>1.0 or 2 x baseline
  • Mental status or neurological changes
  • Acute stroke or clinical concern for stroke
  • Pregnancy
  • Allergy to arginine
  • Previous hospitalization \< 7 days
  • Use of inhaled nitric oxide, sildenafil or arginine within the last 14 days
  • Not an appropriate candidate in the investigator's judgement

The study team makes the final eligibility decision.

Where it is enrolling

  • Atlanta, Georgia, United States

Questions & answers

Do participants get paid in this trial?

This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.

How long does this study last?

The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.

Who can join this trial?

This study is enrolling all sexes, 7 years to 21 years. The study team makes the final eligibility decision.

Where is this trial taking place?

This study is enrolling now at Atlanta, Georgia, United States. Enter your location above to see the nearest enrolling site and check your eligibility.

Explore other conditions

BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.